American Vanguard
Makes crop-protection, biological, and precision-application products for agricultural and non-crop markets.
Something off on this page? Send us feedback.
Profile
Sells synthetic, biological, and biorational products through AMVAC for U.S. crop, U.S. non-crop, and international markets. The business reports one segment, with economics shaped by acquired or licensed chemistries, direct international distribution, product regulation, and manufacturing-footprint changes.
Manufactures, formulates, packages, and sells specialty crop-protection and non-crop products through AMVAC. The portfolio spans Proven Chemistries, GreenSolutions biological and biorational products, and Precision Ag Technologies, including SmartBox+ and SIMPAS.
Serves U.S. crop and non-crop channels alongside international agricultural markets through subsidiaries and distributors in Latin America, Australia, New Zealand, India, and other territories. The business reports one operating segment, so product performance is managed through consolidated market opportunities rather than separate product-segment reporting.
Growth has depended on acquired and licensed chemistries, distribution expansion, and technical service in niche crop and non-crop markets. Product registrations, DCPA/Dacthal removal, and the Los Angeles manufacturing reset shape the current operating base.
Company facts
Key statistics
Year to date −42.0% · Average volume (30d) 271.1K
Analysts
Ratings
Target range
Latest analyst notes
No analyst notes in the last 24 months.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | $0.09 | −$0.34 | −477.8% | $135.0M | $116.8M | −13.5% | −4.37% |
| May 6, 2026Q1 FY26 | −$0.06 | −$0.14 | −133.3% | $120.0M | $123.6M | +3.0% | +2.41% |
| Mar 16, 2026Q4 FY25 | $0.28 | $0.06 | −78.6% | $163.0M | $150.7M | −7.6% | −14.00% |
| Nov 10, 2025Q3 FY25 | −$0.08 | −$0.18 | −125.0% | $128.0M | $119.3M | −6.8% | −3.75% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $115.8M | $129.3M | $119.3M | $150.7M | $123.6M | $116.8M | |
| Gross profit | $30.2M | $40.5M | $34.2M | $42.6M | $38.4M | $34.7M | |
| Operating income | −$4.3M | $4.4M | −$6.5M | $8.0M | $2.6M | −$303.0K | |
| Net income | −$8.5M | −$849.0K | −$12.4M | −$28.2M | −$4.1M | −$9.9M | |
| Diluted EPS | −$0.30 | −$0.03 | −$0.43 | −$0.97 | −$0.14 | −$0.34 | |
| Gross margin | 26.1% | 31.4% | 28.7% | 28.3% | 31.1% | 29.7% | |
| Operating margin | -3.7% | 3.4% | -5.5% | 5.3% | 2.1% | -0.3% |
Fiscal years (4-quarter sums)FY21 $557.7M · FY22 $609.5M · FY23 $579.4M · FY24 $547.3M · FY25 $515.1M
Revenue by product · FY25
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $43.9M · Total debt $284.1M · Total assets $635.3M · Shareholders' equity $181.4M
Dividends
Last raised to $0.03 from $0.025 in Dec 2022.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 26, 2024 | Jun 26 | Jul 10 | $0.03 | |
| Mar 26, 2024 | Mar 27 | Apr 10 | $0.03 | |
| Dec 28, 2023 | Dec 29 | Jan 12 | $0.03 | |
| Sep 21, 2023 | Sep 22 | Oct 6 | $0.03 | |
| Jun 27, 2023 | Jun 28 | Jul 14 | $0.03 | |
| Mar 23, 2023 | Mar 24 | Apr 14 | $0.03 | |
| Dec 27, 2022 | Dec 28 | Jan 11 | $0.03 | raised from $0.025 |
| Sep 22, 2022 | Sep 23 | Oct 7 | $0.025 |
Ownership
Shares outstanding 28.61M · Float 27.58M · 96.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 2.08M | 7.27% | 13F | May 13, 2026 |
| Wellington Management Group LLP | 1.65M | 5.79% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 1.14M | 3.99% | 13F | May 15, 2026 |
| Dimensional Fund Advisors LP | 1.04M | 3.65% | 13F | May 7, 2026 |
| Two Sigma Investments, LP | 746.2K | 2.61% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Keith M. Rosenbloom | director | −556,580 | $2.20 |
| Aug 17, 2026 | Steven D. Macicek | director | +19,000 | $2.09 |
| Jun 3, 2026 | Douglas Kaye | officer: CHIEF EXECUTIVE OFFICER | +5,000 | $2.50 |
| May 12, 2026 | Patrick E. Gottschalk | director | +20,000 | $2.92 |
| May 13, 2026 | Patrick E. Gottschalk | director | +20,000 | $2.95 |
Peers
- FMC
Broad crop-protection rival across insecticides, herbicides, and biologicals
- Corteva
Large crop-protection platform overlapping in herbicides and biologicals
- Scotts Miracle-Gro
Non-crop rival in lawn, garden, weed, pest, and disease controls
- Deere & Company
Precision-application rival at the crop-protection delivery layer
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| American Vanguard | $2.20 | −0.68% | $62.6M | — | — | 0.1 | −9.7% |
| FMC | $11.32 | 0.00% | $1.42B | — | 8.0 | 0.4 | −17.5% |
| Corteva | $83.90 | −0.04% | $56.11B | 55.6 | 21.4 | 3.2 | −1.2% |
| Scotts Miracle-Gro | $60.43 | −0.03% | $3.52B | 52.5 | 13.3 | 1.0 | −1.3% |
| Deere & Company | $630.06 | −0.02% | $170.15B | 35.0 | 30.2 | 3.6 | +7.0% |
| Median | 52.5 | 17.4 | 2.1 | −1.3% |